Chiou Fang Kuan, Ng Lay Queen, Loh Wenyin
Gastroenterology, Hepatology & Nutrition Service, Paediatric Medicine, Kandang Kerbau Women's and Children's Hospital (KKH), Singapore, Singapore.
Allergy Service, Paediatric Medicine, Kandang Kerbau Women's and Children's Hospital (KKH), Singapore, Singapore.
Transl Gastroenterol Hepatol. 2024 Aug 23;9:69. doi: 10.21037/tgh-24-34. eCollection 2024.
Eosinophilic gastrointestinal disorders (EGID) are a heterogeneous group of conditions, comprising eosinophilic esophagitis (EoE) and non-EoE EGID which have gained considerable research interest. There are likely to be differences in disease characteristics between populations with distinct dietary, environmental and cultural backgrounds. However much of our understanding on EGID have come from studies from Europe and North America. The aim of this review is to summarize the recent developments and updates in EGID focusing on disease phenotype specifically in Asian patients, and identify opportunities for future research pertaining to disease profile in the Asian population.
Original studies, systematic reviews, meta-analyses and review articles up to March 2024 were systematically searched on PubMed, with specific focus on newer studies published in the past 10 years. Case reports, conference abstracts and articles that were not published in the English language were excluded.
Prevalence and incidence of EoE and non-EoE EGID have reportedly increased globally over time, but population-based studies are lacking in Asia. Based on heterogeneous data from a limited number of studies from Asia, there are features in epidemiology, clinical phenotype, and treatment response that may be appreciably distinct in Asian patients with EoE and non-EoE EGID, as compared to the Western patient population. Moreover, the efficacy of novel biologic therapies such as dupilumab in the Asian population has not been well-defined.
There is a lack of robust data on many basic aspects of EGID in Asia. There is a pressing need to bridge this gap by building research networks and collaborations across wider regions in Asia, to gather high-quality, multicenter data using standardized and uniform criteria and build a more accurate understanding of EGID in Asian patients.
嗜酸性粒细胞性胃肠道疾病（EGID）是一组异质性疾病，包括嗜酸性粒细胞性食管炎（EoE）和非EoE的EGID，已引起了相当多的研究关注。在具有不同饮食、环境和文化背景的人群中，疾病特征可能存在差异。然而，我们对EGID的大部分了解都来自欧洲和北美的研究。本综述的目的是总结EGID的最新进展和更新情况，特别关注亚洲患者的疾病表型，并确定与亚洲人群疾病特征相关的未来研究机会。
截至2024年3月，在PubMed上系统检索了原始研究、系统评价、荟萃分析和综述文章，特别关注过去10年发表的较新研究。排除病例报告、会议摘要和非英文发表的文章。
据报道，全球范围内EoE和非EoE的EGID的患病率和发病率随时间推移有所增加，但亚洲缺乏基于人群的研究。根据来自亚洲有限数量研究的异质性数据，与西方患者群体相比，亚洲EoE和非EoE的EGID患者在流行病学、临床表型和治疗反应方面可能存在明显差异。此外，新型生物疗法如度普利尤单抗在亚洲人群中的疗效尚未明确界定。
亚洲在EGID许多基本方面缺乏有力数据。迫切需要通过在亚洲更广泛地区建立研究网络和合作来弥合这一差距，使用标准化和统一标准收集高质量的多中心数据，并更准确地了解亚洲患者的EGID。
